KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...
Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report ...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par bought 14,562 shares of the firm’s stock in a transaction on Monday, February 3rd. The ...
Fintel on MSN3d
JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform RecommendationFintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a ...
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. As of January 28, 2025, the average ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback